Lewy Body Disease (PD, DLB)

Lewy body disease — encompassing Parkinson disease (PD), Parkinson disease dementia (PDD), and dementia with Lewy bodies (DLB) — is a synucleinopathy characterized by the accumulation of misfolded α-synuclein protein in neurons. Lewy bodies are the pathologic signature, first described by Friedrich Lewy in 1912. The disease has expanded from a movement disorder (PD) into a broader spectrum that includes cognitive and behavioral disorders (DLB) and autonomic dysfunction (multiple system atrophy is a related but distinct synucleinopathy). This page covers Lewy body pathology and the clinical-pathologic correlations across the spectrum.

The Lewy Body

Histology

  • Eosinophilic intracytoplasmic inclusion in neuronal cytoplasm.
  • Dense central core surrounded by a clear halo in classical (brainstem-type) Lewy bodies on H&E.
  • Cortical Lewy bodies: less well-formed, lack the central core; visible mainly with IHC.
  • α-synuclein IHC: highly sensitive (phospho-Ser129 antibodies most specific).
  • Ubiquitin IHC: positive (older detection method).

Lewy Neurites

α-Synuclein-positive thread-like structures in neuronal processes. Often more numerous than Lewy bodies. Particularly prominent in CA2-3 hippocampus in DLB.

Selective Vulnerability

Specific neuronal populations are preferentially affected:

  • Substantia nigra pars compacta (ventrolateral tier first): dopaminergic neurons; substrate of motor PD.
  • Locus coeruleus: noradrenergic.
  • Dorsal motor nucleus of vagus: parasympathetic.
  • Nucleus basalis of Meynert: cholinergic.
  • Pedunculopontine and laterodorsal tegmental nuclei: cholinergic; REM sleep behavior disorder.
  • Olfactory bulb: often first involved.
  • Sympathetic ganglia: autonomic dysfunction.
  • Enteric nervous system: GI dysmotility, constipation.
  • Amygdala: behavioral features.
  • Cortex: cognitive features (in DLB and PDD).

Braak Staging of Lewy Body Pathology

Separate from Braak AD staging; tracks ascending spread of α-synuclein pathology:

Stage Region Clinical correlation
1 Olfactory bulb / dorsal motor nucleus of vagus Prodromal: anosmia, constipation
2 Lower brainstem (raphe, locus coeruleus) Prodromal: REM sleep behavior disorder, depression
3 Substantia nigra, basal forebrain Motor PD onset
4 Limbic cortex, mesocortex Mild cognitive features, more motor
5 Higher cortex (sensory association) Cognitive decline
6 Premotor and motor cortex Severe disease

The hypothesis of gut-to-brain spread (via vagus nerve from enteric nervous system) is increasingly supported and may have implications for early intervention.

Parkinson Disease (PD)

Pathology

  • Depigmentation of substantia nigra pars compacta (visible grossly).
  • Loss of nigral dopaminergic neurons.
  • Lewy bodies in remaining neurons.
  • Variable cortical Lewy bodies.
  • α-synuclein-positive Lewy neurites.

Clinical

  • Asymmetric onset: rest tremor, rigidity, bradykinesia.
  • Non-motor features (often preceding motor): anosmia, constipation, RBD, depression, autonomic dysfunction.
  • Good response to L-dopa initially.
  • Progression: motor fluctuations, dyskinesias, postural instability, eventually cognitive decline.
  • Dementia in ~80% over 15-20 years (PDD).

Dementia with Lewy Bodies (DLB)

Pathology

  • Cortical Lewy bodies + nigral Lewy bodies.
  • Often coexisting AD pathology (50-70%).
  • α-synuclein IHC reveals cortical involvement that H&E misses.

Clinical (McKeith Criteria)

Core features:

  • Fluctuating cognition with pronounced variations in attention/alertness.
  • Recurrent visual hallucinations (often well-formed, often non-threatening, often of people or animals).
  • REM sleep behavior disorder (RBD).
  • Parkinsonism.

Supportive: severe neuroleptic sensitivity, low DAT uptake on imaging (DaTscan), MIBG reduced cardiac uptake (sympathetic denervation).

Distinguishing DLB from PDD

The “1-year rule”: if dementia precedes or coincides within 1 year of parkinsonism = DLB; if parkinsonism precedes dementia by > 1 year = PDD. The pathology is similar; the clinical onset distinguishes.

Multiple System Atrophy (MSA)

Related but distinct synucleinopathy:

  • α-synuclein accumulates in glial cytoplasmic inclusions (GCIs, Papp-Lantos bodies) within oligodendrocytes — distinct from neuronal Lewy bodies.
  • Selective vulnerability: striatonigral degeneration (MSA-P) or olivopontocerebellar atrophy (MSA-C); mixed common.
  • Autonomic dysfunction prominent.
  • “Hot cross bun” sign on MRI of pons.
  • Poor L-dopa response.
  • Faster progression than PD.

Genetic Lewy Body Disease

  • SNCA (α-synuclein gene) mutations: A53T, A30P, E46K; very rare; autosomal dominant.
  • SNCA gene duplications/triplications: dose-dependent severity.
  • LRRK2: most common genetic cause; both familial and sporadic.
  • GBA (glucocerebrosidase): heterozygous mutations strongly increase PD risk; cause Gaucher disease when homozygous.
  • PARK genes: PARK7 (DJ-1), PARK2 (parkin), PARK6 (PINK1) — early-onset, autosomal recessive.
  • VPS35: autosomal dominant late-onset.

Prodromal Lewy Body Disease

Lewy body disease often has a 10-20 year prodrome:

  • REM sleep behavior disorder (RBD): highly predictive of synucleinopathy — 60-80% of polysomnographically confirmed RBD patients develop PD, DLB, or MSA over 10-15 years.
  • Anosmia: early loss of smell.
  • Constipation: from enteric nervous system synucleinopathy.
  • Autonomic dysfunction: orthostatic hypotension, urinary, sexual.
  • Depression and anxiety.
  • Subtle motor signs.

The recognition of prodromal disease opens windows for early intervention if disease-modifying therapy emerges.

Biomarkers

  • α-synuclein seed amplification assay (RT-QuIC, syn-SAA): detects misfolded α-synuclein in CSF, skin, olfactory mucosa. High sensitivity and specificity for PD, DLB. Skin biopsy is becoming a key diagnostic tool.
  • DAT-SPECT (DaTscan): shows reduced presynaptic dopaminergic activity in PD, DLB.
  • MIBG cardiac scintigraphy: reduced uptake in PD/DLB (sympathetic cardiac denervation) vs preserved in MSA — distinguishes them.
  • Olfactory testing: anosmia common in PD/DLB.
  • Polysomnography: confirms RBD.

Treatment

  • L-dopa: cornerstone of motor symptom management.
  • Dopamine agonists, MAO-B inhibitors, COMT inhibitors.
  • Cholinesterase inhibitors for cognitive symptoms in DLB/PDD.
  • Deep brain stimulation (STN, GPi) for motor symptoms in refractory PD.
  • Avoid neuroleptics in DLB (severe neuroleptic sensitivity).
  • α-synuclein-targeting therapies in clinical trials.

🔍 Did You Know?

The discovery and validation of the α-synuclein seed amplification assay (syn-SAA) has fundamentally changed our ability to diagnose synucleinopathies during life. The assay exploits the templating ability of misfolded α-synuclein: a small sample of CSF, skin, or olfactory mucosa is added to a reaction containing recombinant α-synuclein and a fluorescent dye that binds to amyloid β-sheets. If any seeds of misfolded α-synuclein are present, they template progressive conversion of the substrate over hours of repeated agitation, with fluorescence increasing as the assay proceeds. The result: a sensitive (90%+) and specific (95%+) test for Lewy body disease in living patients. The assay has revealed that α-synuclein pathology can be detected in skin biopsy and in CSF, often years before clinical motor symptoms appear. The technique is now entering clinical practice for the diagnosis of PD and DLB, distinguishing them from related disorders, and identifying prodromal disease. The 2023 development of α-synuclein-targeting antibody therapies and antisense oligonucleotides in trials means that — for the first time — we may soon have disease-modifying therapy for synucleinopathies, and the syn-SAA may become the screening tool for trial inclusion. Synucleinopathy is following the trajectory that Alzheimer biomarkers traveled a decade earlier: from a histologic post-mortem diagnosis to a biomarker-defined antemortem entity with disease-modifying therapy on the horizon.

Pitfalls and Pearls

  • Lewy body: eosinophilic intracytoplasmic inclusion; α-synuclein IHC positive (phospho-Ser129 most sensitive).
  • Substantia nigra pars compacta loss + Lewy bodies: PD.
  • Cortical Lewy bodies: DLB.
  • Glial cytoplasmic inclusions (Papp-Lantos): MSA — distinct from Lewy bodies (oligodendrocytic rather than neuronal).
  • Braak Lewy staging: olfactory/vagus → brainstem → SN → limbic → neocortex.
  • RBD: prodromal feature of synucleinopathy; 60-80% develop PD/DLB/MSA over 15 years.
  • Anosmia, constipation, RBD: classical prodromal triad.
  • 1-year rule for DLB vs PDD: dementia ≤ 1 year of parkinsonism = DLB; > 1 year apart = PDD.
  • McKeith DLB criteria: fluctuating cognition + visual hallucinations + RBD + parkinsonism.
  • Neuroleptic sensitivity in DLB: avoid first-generation antipsychotics; use quetiapine or pimavanserin if needed.
  • LRRK2: most common genetic cause of PD.
  • GBA heterozygous mutation: strongest genetic risk factor.
  • α-synuclein seed amplification assay (syn-SAA): skin biopsy + CSF; high sensitivity/specificity; emerging clinical use.
  • MIBG cardiac imaging: low in PD/DLB, preserved in MSA.
  • DaTscan: reduced presynaptic dopaminergic activity in PD/DLB; not in MSA-C predominantly.

References

  1. Love S, Budka H, Ironside JW, Perry A, eds. Greenfield’s Neuropathology. 9th ed. CRC Press; 2015.
  2. Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197-211.
  3. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100.
  4. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591-1601.
  5. Siderowf A, Concha-Marambio L, Lafontant DE, et al; PPMI Authors. Assessment of heterogeneity among participants in the PPMI cohort using α-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023;22(5):407-417.
  6. Wenning GK, Stankovic I, Vignatelli L, et al. The MDS criteria for multiple system atrophy. Mov Disord. 2022;37(6):1131-1148.